| AMCIL Limited (AMH) ORDINARY FULLY PAID |
Financials |
$301 |
Letter to Shareholders - Shareholder Information Meetings
|
28 Apr 2025 9:10AM |
$1.050 |
$0.950 |
fallen by
9.52%
|
|
| Pengana Capital Group Limited (PCG) ORDINARY FULLY PAID |
Financials |
$72 |
Update - Notification of buy-back - PCG
|
28 Apr 2025 9:09AM |
$0.740 |
$0.730 |
fallen by
1.35%
|
|
| Cleo Diagnostics Ltd (COV) ORDINARY FULLY PAID |
Health Care |
$75 |
CLEO to Fast Track Development of Ovarian Cancer Test
|
28 Apr 2025 9:09AM |
$0.440 |
$0.550 |
risen by
25%
|
|
COV - Price-sensitive ASX Announcement
Full Release
Key Points
- Cleo Diagnostics Ltd (CLEO) is advancing the COV ovarian cancer diagnostic test.
- The company is implementing a fast-track strategy to accelerate COV’s development and regulatory approval.
- COV uses a proprietary biomarker panel for sensitive and specific detection of ovarian cancer.
- Recent clinical validation steps and regulatory planning have been successfully completed.
- CLEO is pursuing strategic partnerships to facilitate rapid commercialisation.
- There is a significant market need for improved ovarian cancer diagnostics.
- The COV test targets a large and underserved global market.
- Management anticipates value creation for shareholders via accelerated development and commercialisation.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Recce Pharmaceuticals Ltd (RCE) ORDINARY FULLY PAID |
Health Care |
$130 |
Recce Enters into USA Department of Defense R&D Agreement
|
28 Apr 2025 9:09AM |
$0.290 |
$0.450 |
risen by
55.17%
|
|
RCE - Price-sensitive ASX Announcement
Full Release
Key Points
- Recce Pharmaceuticals entered into a Cooperative Research and Development Agreement (CRADA) with the U.S. Department of Defense’s Defense Threat Reduction Agency (DTRA).
- The agreement aims to evaluate Recce’s lead anti-infective compound, RECCE® 327 (R327), for its in vitro and in vivo activity against select biothreat pathogens.
- Collaboration is designed to advance R327’s development for defense and security applications.
- Recce will retain all rights to its technology and any resultant intellectual property from the partnership.
- This partnership reflects Recce’s ongoing strategy of collaborating with international government agencies.
- The agreement is expected to enhance the global profile of Recce and its products, particularly in the area of defense and emerging infectious diseases.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Australian United Investment Company Limited (AUI) ORDINARY FULLY PAID |
Financials |
$1,376 |
Update - Notification of buy-back - AUI
|
28 Apr 2025 9:09AM |
$10.360 |
$11.110 |
risen by
7.24%
|
|
| Regal Investment Fund (RF1) ORDINARY UNITS FULLY PAID |
Financials |
$715 |
Weekly Estimate NTA for 25.04.2025
|
28 Apr 2025 9:08AM |
$2.860 |
$3.410 |
risen by
19.23%
|
|
| Neuren Pharmaceuticals Limited (NEU) ORDINARY FULLY PAID |
Health Care |
$1,602 |
Update - Notification of buy-back - NEU
|
28 Apr 2025 9:08AM |
$11.340 |
$12.650 |
risen by
11.55%
|
|
| Gorilla Gold Mines Ltd (GG8) ORDINARY FULLY PAID |
Materials |
$264 |
Quarterly Activities/Appendix 5B Cash Flow Report
|
28 Apr 2025 9:08AM |
$0.475 |
$0.360 |
fallen by
24.21%
|
|
GG8 - Price-sensitive ASX Announcement
Full Release
Key Points
- Quarterly Activities and Appendix 5B Cash Flow Report released for the period ending 31 March 2024
- Continued gold exploration and early-stage development at the Wa Project in the Ashanti gold belt, Ghana
- Commencement of maiden diamond drilling program following successful mapping, soil sampling, and geophysical surveys
- Grant of two new prospecting licenses, increasing total landholding
- Expenditures focused on exploration, drilling, and project development activities
- Maintenance of a prudent cash position throughout the reporting quarter
- Ongoing engagement with local communities and stakeholders
- No gold production or receipts from customers during the quarter
- Appendix 5B outlines detailed cash flow, with primary outflows related to exploration and staff costs
- Company remains committed to aggressive exploration and value creation for shareholders
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Sierra Nevada Gold Inc. (SNX) CDI 1:1 US PERSON PROHIBITED EXCLUDING QIB |
Materials |
$20 |
Quarterly Activities/Appendix 5B Cash Flow Report
|
28 Apr 2025 9:08AM |
$0.017 |
$0.041 |
risen by
141.18%
|
|
SNX - Price-sensitive ASX Announcement
Full Release
Key Points
- Quarterly Activities/Appendix 5B Cash Flow Report released for the quarter ending 31 March 2023.
- Active exploration across multiple Nevada-based gold and copper projects, including New Pass, Blackhawk, and Colorback.
- Ongoing drilling and geophysical survey programs yielding encouraging results and indicating mineralization potential.
- Assay results from drilling support continued exploration and target generation.
- Permit applications and preparations for subsequent drilling campaigns underway.
- Exploration and evaluation expenditures formed the majority of operational cash outflows.
- Company reported a strong cash position at quarter end to fund future work programs.
- No mining production or development activities reported during the quarter.
- Detailed cash flow breakdown provided in the Appendix 5B as per ASX reporting requirements.
- Strategic focus remains on expanding exploration and identifying significant gold and copper resources in Nevada.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Patagonia Lithium Ltd (PL3) ORDINARY FULLY PAID |
Materials |
$36 |
Notice of 2025 AGM and Proxy Form
|
28 Apr 2025 9:07AM |
$0.059 |
$0.175 |
risen by
196.61%
|
|
| KKR Credit Income Fund (KKC) ORDINARY UNITS FULLY PAID |
Financials |
$653 |
Net Tangible Asset Backing
|
28 Apr 2025 9:07AM |
$2.230 |
$2.025 |
fallen by
9.19%
|
|
| Latitude Group Holdings Limited (LFS) ORDINARY FULLY PAID |
Financials |
$951 |
CEO Share Trading
|
28 Apr 2025 9:07AM |
$1.140 |
$0.915 |
fallen by
19.74%
|
|
| Killi Resources Limited (KLI) ORDINARY FULLY PAID |
Materials |
$27 |
Board and Management Update
|
28 Apr 2025 9:07AM |
$0.040 |
$0.195 |
risen by
387.50%
|
|
KLI - Price-sensitive ASX Announcement
Full Release
Key Points
- Killi Resources Limited appointed Mr. Jonathan Battershill as its new Managing Director.
- Former Managing Director Ms. Kathryn Cutler will take on the role of Technical Director.
- The company highlighted the strong technical and corporate backgrounds of its Board members.
- Killi is focused on advancing gold and copper exploration projects in Western Australia and Queensland.
- The Board restructure aims to position the company for its next phase of exploration and corporate growth.
- Shareholder value remains a key focus for the company through ongoing resource development initiatives.
- The announcement reflects Killi’s proactive approach in strengthening its leadership and operational capabilities.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Zip Co Limited (ZIP) ORDINARY FULLY PAID |
Financials |
$2,268 |
Update - Notification of buy-back - ZIP
|
28 Apr 2025 9:06AM |
$1.675 |
$1.785 |
risen by
6.57%
|
|
| 4DS Memory Limited (4DS) ORDINARY FULLY PAID |
Information Technology |
$21 |
imec shipment of Sixth Platform Lot
|
28 Apr 2025 9:06AM |
$0.028 |
$0.010 |
fallen by
64.29%
|
|
| Resimac Group Limited (RMC) ORDINARY FULLY PAID |
Financials |
$360 |
Update - Notification of buy-back - RMC
|
28 Apr 2025 9:05AM |
$0.850 |
$0.910 |
risen by
7.06%
|
|
| Pengana Global Private Credit Trust (PCX) ORDINARY UNITS FULLY PAID |
Financials |
$226 |
Update - Notification of buy-back - PCX
|
28 Apr 2025 9:05AM |
$1.980 |
$1.980 |
fallen by
0%
|
|
| Elementos Limited (ELT) ORDINARY FULLY PAID |
Materials |
$150 |
Oropesa Tin Project DFS & Ore Reserve Presentation - Updated
|
28 Apr 2025 9:04AM |
$0.076 |
$0.345 |
risen by
353.95%
|
|
| Zeotech Limited (ZEO) ORDINARY FULLY PAID |
Materials |
$125 |
Quarterly Activities/Appendix 5B Cash Flow Report
|
28 Apr 2025 9:04AM |
$0.079 |
$0.061 |
fallen by
22.78%
|
|
ZEO - Price-sensitive ASX Announcement
Full Release
Key Points
- Zeotech Limited (ZEO) released its Quarterly Activities and Appendix 5B Cash Flow Report covering the period ending 31 March 2024.
- ZEO continued the advancement of its kaolin and zeolite-based mineral technology projects, focusing on the commercialisation of manufactured zeolites.
- Key activities included progressing the renewable energy-based zeolite manufacturing project and advancing pilot plant operations to scale up the production process.
- The company reported updates on its collaboration with the University of Queensland and Cooperative Research Centre for Contamination Assessment and Remediation of the Environment (CRC CARE) for product development and environmental applications.
- Zeotech continued its research and development in areas including PFAS remediation, emissions management, and agricultural applications for its zeolite products.
- During the quarter, the company secured additional intellectual property rights relating to its proprietary zeolite manufacturing technology.
- Cash outflows were primarily attributed to research and development, staff costs, and operational expenses linked to project advancement.
- The company ended the quarter with a strong cash position and no significant financing activities, indicating prudent financial management.
- Significant attention was given to the ongoing pilot plant operations, which are seen as pivotal to ZEO's near-term commercialisation strategy.
- ZEO highlighted plans for the next quarter, including further pilot plant optimisation, commercial partnership development, and expanded product application trials.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| AMCIL Limited (AMH) ORDINARY FULLY PAID |
Financials |
$301 |
Update - Notification of buy-back - AMH
|
28 Apr 2025 9:04AM |
$1.050 |
$0.950 |
fallen by
9.52%
|
|
| Bowen Coking Coal Limited (BCB) ORDINARY FULLY PAID |
Materials |
$8 |
Quarterly Activities/Appendix 5B Cash Flow Report
|
28 Apr 2025 9:04AM |
$0.320 |
$0.075 |
fallen by
76.56%
|
|
BCB - Price-sensitive ASX Announcement
Full Release
Key Points
- Coal shipments commenced from the Burton Complex, marking a key operational milestone.
- Bluff Mine achieved a significant increase in production and sales volume.
- Exploration and development activities continued across other tenements, including Broadmeadow East, Isaac River, and Hillalong.
- Strategic partnerships and offtake agreements supported operational and financial progress.
- The company reported a quarter-on-quarter increase in revenue from coal sales.
- Operational cash flow turned positive, indicating improved financial performance.
- Significant investments were made in mine development, equipment, and infrastructure.
- The report details cash flows, including receipts, payments, investing, and financing activities.
- Bowen continues active cost management and capital discipline across its operations.
- At the end of the quarter, the company disclosed its cash balance and financial position.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Rimfire Pacific Mining Limited (RIM) ORDINARY FULLY PAID |
Materials |
$39 |
Notice of General Meeting/Proxy Form
|
28 Apr 2025 9:04AM |
$0.023 |
$0.014 |
fallen by
39.13%
|
|
| PYC Therapeutics Limited (PYC) ORDINARY FULLY PAID |
Health Care |
$1,106 |
Presentation of Clinical Proof of Concept in Lead Program
|
28 Apr 2025 9:02AM |
$1.115 |
$1.125 |
risen by
0.90%
|
|
PYC - Price-sensitive ASX Announcement
Full Release
Key Points
- PYC Therapeutics presented clinical proof of concept for VP-001 in PRPF31-mediated Retinitis Pigmentosa.
- VP-001 is an RNA-based therapy designed to correct the underlying genetic defect in patients.
- Early clinical trial data demonstrate a favorable safety profile for VP-001.
- Biological activity was observed in initial trial participants, indicating potential therapeutic benefit.
- The company emphasized the unmet need in inherited retinal diseases and the lack of approved therapies for this condition.
- Clinical trial design included measurement of safety, tolerability, and biomarkers of efficacy.
- VP-001 is administered via intravitreal injection, a standard ophthalmic delivery route.
- PYC outlined its strategic vision to expand its pipeline of precision RNA therapies for ophthalmology.
- The company aims to leverage its platform to address additional genetic eye diseases.
- PYC Therapeutics plans to continue advancing VP-001 through clinical development and regulatory engagement.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Butn Limited (BTN) ORDINARY FULLY PAID |
Financials |
$12 |
Quarterly Appendix 4C Cash Flow Report
|
28 Apr 2025 9:02AM |
$0.099 |
$0.031 |
fallen by
68.69%
|
|
BTN - Price-sensitive ASX Announcement
Full Release
Key Points
- Butn Limited reported strong year-on-year revenue growth for the quarter ended 31 March 2023.
- Total cash receipts from customers were $153.3 million, representing a 29% increase versus the prior corresponding period.
- Net cash used in operating activities was $0.4 million for the quarter.
- Payments to suppliers and employees totaled $2 million.
- There was ongoing investment in technology and operational capabilities.
- The company’s balance sheet was strengthened through prudent cash flow management.
- No significant related party transactions occurred other than director remuneration.
- The company remains focused on expanding product offerings and partnerships.
- Management commentary included risk assessment and outlook for future quarters.
- The report was lodged with the ASX on 28 April 2023.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Butn Limited (BTN) ORDINARY FULLY PAID |
Financials |
$12 |
Quarterly Activities Report
|
28 Apr 2025 9:01AM |
$0.099 |
$0.031 |
fallen by
68.69%
|
|
BTN - Price-sensitive ASX Announcement
Full Release
Key Points
- Record quarterly originations and cash receipts achieved.
- Strong growth in transaction volume and revenue compared to previous periods.
- Expansion of technology platforms and product offerings, including the launch of Butn X.
- Strengthened strategic partnerships, notably with MYOB.
- Improved funding efficiency and capital management.
- Enhanced customer acquisition and retention metrics.
- Operational focus on scalable technology and automation.
- Positive outlook supported by a strengthened balance sheet and growth initiatives.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
Call 1300 880 160
Start a chat
Schedule a call
